It is conceivable that alternative treatments could be used for patients whose TNBC tumours display the characteristics identified here as associated with potential anthracycline resistance, namely active IFN signalling between CAFs and claudin-low tumour cells (CAF IFNβ expression/cancer cell MX1 expression; Fig. 5). The gene discussed is MX1; the disease is neoplasm.